"); document.write(""); } //-->
![]() |
|
||||||||||||||||||||||
|
|
What is MIACALCIN Nasal Spray?
MIACALCIN Nasal Spray is a prescription medication recommended for the treatment of postmenopausal osteoporosis in women more than 5 years after menopause who have low bone mass, and who can't or won't take estrogens, or for whom estrogens are not an option. MIACALCIN Nasal Spray should be used along with adequate amounts of calcium and vitamin D every day.
How long has MIACALCIN Nasal Spray been on the market? MIACALCIN is approved for the treatment of postmenopausal osteoporosis in more than 70 countries, and the nasal spray was launched in the United States in late 1995. Based on more than 20 years of clinical trials in the United States and abroad, its active ingredient calcitonin-salmon has been shown to be an effective treatment for postmenopausal osteoporotic women. How is MIACALCIN Nasal Spray different from other nasal sprays? Unlike most nasal sprays, MIACALCIN Nasal Spray doesn't have to be inhaled. It delivers a gentle spray that is barely noticeableand the recommended dose is one spray, once a day.
As with any medication, some side effects can occur when using MIACALCIN Nasal Spray. Side effects may include: nasal symptoms (runny nose, crusting, nosebleed, etc), back and/or joint pain, and headache. These side effects tend to be mild and disappear quickly; however, in some cases, the doctor or healthcare provider may recommend temporarily discontinuing the medication until symptoms stop.
If people experience side effects after using MIACALCIN Nasal Spray, they should contact their doctor or healthcare provider. Also, because calcitonin-salmon is a protein, the potential for a systemic allergic reaction exists. People who are allergic to calcitonin-salmon should not use this medication. For more information about MIACALCIN Nasal Spray, please contact a physician or healthcare provider or click on Prescribing Information. To view information for patients click here. |
||||||||||||||||
|
Home | Understanding Osteoporosis | |||||||||||||||||
| |||||||||||||||||